



NTX enhances corneal repair in T1D

## Technology Summary

Diabetes often presents with systemic ocular surface complications including dry eye, keratopathy, and eye sensitivity. Studies have indicated 54% prevalence of asymptomatic and symptomatic Dry Eye Syndrome in diabetes. Penn State inventors have demonstrated that dysregulation of opioid growth factor (OGF)-OGF receptor (OGFr) regulation in the diabetic cornea is associated with the onset and magnitude of ocular surface complications. Dysregulation of the OGF-OGFr axis is present in both uncontrolled and insulin-controlled diabetic animal models. Penn State inventors have shown that the OGF-OGFr axis can be modulated by Naltrexone (NTX), a long-acting opioid receptor antagonist that is currently FDA approved for the management of drug, alcohol, and nicotine dependence. Topical application of NTX enhances corneal repair and increases tear production in type 1 diabetic animal models. Topical application of NTX also resulted in the return of corneal hypersensitivity and increased tear production in type 2 diabetes animal models. The inventors have further established a novel, non-toxic eye drop formulation of NTX.

## Application & Market Utility

Dry eye is a disorder of increasing prevalence that affects tear production. Chronic dryness leads to pain and irritation and often impedes normal daily activities. Sustained dry eye can lead to permanent damage and result in vision loss, increased risk of infection, and scarring of the cornea. Currently, the most frequently prescribed therapy by vision specialists is tear supplementation (e.g., lubricants). Lubricants do not treat the cause of dry eye, can be expensive, and need to be taken for life.

## Next Steps

Phase I clinical validation of naltrexone for the treatment of dry eye is complete. A protocol for Phase II is available. Penn State seeks an industry partner and/or licensee to complete US clinical validation.

TECHNOLOGY READINESS LEVEL

8-10

### Seeking

Investment | Licensing | Research

### Keywords

- Dry Eye
- Diabetic Dry Eye
- Human Therapeutic
- Naltrexone
- Phase II Study

### Researchers

**Patricia McLaughlin, MS, DEd**

Professor of Neural and Behavioral Sciences

[Online Bio](#)

**Joseph Sassani, MD, MHA**

Professor and Vice Chair for Clinical Affairs of Ophthalmology and Professor of Pathology and Laboratory Medicine

[Website](#)

**Ian Zagon, MS, PhD**

Distinguished Professor of Neural and Behavioral Sciences

[Website](#)

**Originating College**

College of Medicine

### Office of Technology Management Contact

Long, Melissa

[mkl137@psu.edu](mailto:mkl137@psu.edu)

814-865-5730



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at [invent.psu.edu](http://invent.psu.edu).

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.